One caveat in treating these HER2 mutant breast cancers is a recent report suggesting dual targeting of HER2 and ER pathways may be required for optimal treatment in cases that are also positive for estrogen receptor [23]. This evidence concerns the gene ERBB2 and breast carcinoma.